Phathom Pharmaceuticals is making waves in the biotech industry following a significant upgrade from Barclays. The firm has raised its rating for Phathom, now classified as Overweight, with a price target set at $18. This decision comes in the context of a remarkable surge in prescription fills for its flagship drug, VOQUEZNA, which addresses gastroesophageal reflux disease (GERD) and H. pylori infections.
Impressive Growth Metrics
In the fourth quarter of 2025, Phathom reported a staggering increase in quarterly prescription fills, jumping from 127,000 in the first quarter to 273,000 by the fourth quarter. This robust growth catapulted the company’s revenue to $57.58 million, marking a substantial 94% year-over-year increase. The earnings per share (EPS) also exceeded expectations, coming in at -$0.08 compared to a consensus estimate of -$0.42.
Strong Market Position
The upgrade from Barclays is not merely a reflection of past performance but also an acknowledgment of Phathom’s strategic market positioning. VOQUEZNA benefits from New Chemical Entity exclusivity, which is secured until May 2032. This exclusivity shields the drug from generic competition, laying a solid foundation for sustained revenue growth. Barclays anticipates that this exclusivity will play a crucial role in propelling Phathom’s market share within the GERD and H. pylori treatment sectors.
Positive Outlook for 2026
Analyst Jenna Davidner highlighted that despite a lighter prescription trend in the first quarter of 2026, the overall outlook remains promising. Barclays has set revenue expectations for Phathom ranging from $320 million to $345 million for the fiscal year 2026, with the company poised to achieve operating profitability by the third quarter of that year. This forward-looking perspective underscores the belief that the company is on the verge of a significant revenue ramp.
Financial Health and Risks
Despite the positive developments, it’s essential to acknowledge the risks associated with Phathom. The company currently carries negative stockholders’ equity of -$438.17 million, alongside a $175 million term loan. Additionally, the company faces financial covenants related to its RIFA cash holdings, which start in October 2026. The upcoming weekly prescription reports will be crucial indicators to determine if the softer start to 2026 is a temporary setback or a more pronounced trend.
Analyst Consensus and Market Sentiment
Barclays’ target price of $18, while optimistic, remains lower than the broader analyst consensus of $23.50. Some analysts, like those at Guggenheim, have even set their targets as high as $25, reinforcing a generally bullish sentiment surrounding Phathom. The current share price, which stands around $10.69, presents what many investors consider an attractive entry point, especially given the anticipated growth trajectory.
Future Catalysts
As Phathom navigates the remainder of 2026, several catalysts could propel the stock upward. Weekly prescription data will serve as a key barometer of demand, providing investors with insights into market momentum. Should the company continue to build on its prescription growth and maintain cost controls—evidenced by a decrease in operating expenses from $85.27 million to $55.87 million year-over-year—the road to profitability appears increasingly plausible.
Conclusion
Phathom Pharmaceuticals stands at a pivotal juncture, armed with a promising product and an optimistic growth outlook. While challenges remain, the company’s strategic position in the market and the recent upgrade from Barclays suggest that it may very well be an investment opportunity worth considering. As investors await further developments, Phathom could emerge as a significant player in the biotech landscape.
- Phathom’s prescription fills surged from 127,000 to 273,000 in 2025.
- Barclays upgraded the stock with an $18 price target, citing growth potential.
- VOQUEZNA benefits from exclusivity until May 2032, limiting generic competition.
- The company anticipates reaching operating profitability by Q3 2026.
- Risks include negative equity and upcoming financial obligations.
Read more → 247wallst.com